23 results on '"Bonig, Halvard"'
Search Results
2. Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.
- Author
-
Enßle JC, Campe J, Schwenger A, Wiercinska E, Hellstern H, Dürrwald R, Rieger MA, Wolf S, Ballo O, Steffen B, Serve H, Bonig H, Rabenau HF, Widera M, Ciesek S, Metzler IV, and Ullrich E
- Subjects
- BNT162 Vaccine pharmacology, COVID-19 immunology, Humans, Immunity, Cellular, Multiple Myeloma immunology, SARS-CoV-2 immunology, BNT162 Vaccine therapeutic use, COVID-19 prevention & control, Multiple Myeloma complications, T-Lymphocytes immunology
- Published
- 2022
- Full Text
- View/download PDF
3. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
- Author
-
Jetani H, Navarro-Bailón A, Maucher M, Frenz S, Verbruggen C, Yeguas A, Vidriales MB, González M, Rial Saborido J, Kraus S, Mestermann K, Thomas S, Bonig H, Luu M, Monjezi R, Mougiakakos D, Sauer M, Einsele H, and Hudecek M
- Subjects
- Animals, Cell Line, Tumor, Cytotoxicity, Immunologic, Female, Humans, Leukemia, Myeloid, Acute immunology, T-Lymphocytes immunology, U937 Cells, Antigens, CD immunology, Antigens, Differentiation, Myelomonocytic immunology, Immunotherapy, Adoptive methods, Lectins immunology, Leukemia, Myeloid, Acute therapy
- Abstract
Acute myeloid leukemia (AML) is an attractive entity for the development of chimeric antigen receptor (CAR) T-cell immunotherapy because AML blasts are susceptible to T-cell-mediated elimination. Here, we introduce sialic acid-binding immunoglobulin-like lectin 6 (Siglec-6) as a novel target for CAR T cells in AML. We designed a Siglec-6-specific CAR with a targeting domain derived from the human monoclonal antibody JML-1. We found that Siglec-6 is commonly expressed on AML cell lines and primary AML blasts, including the subpopulation of AML stem cells. Treatment with Siglec-6 CAR T cells confers specific antileukemia reactivity that correlates with Siglec-6 expression in preclinical models, including induction of complete remission in a xenograft AML model in immunodeficient mice (NSG/U937). In addition, we confirmed Siglec-6 expression on transformed B cells in chronic lymphocytic leukemia (CLL), and specific anti-CLL reactivity of Siglec-6 CAR T cells in vitro. Of particular interest, we found that Siglec-6 is not detectable on normal hematopoietic stem and progenitor cells (HSPCs) and that treatment with Siglec-6 CAR T cells does not affect their viability and lineage differentiation in colony-formation assays. These data suggest that Siglec-6 CAR T-cell therapy may be used to effectively treat AML without the need for subsequent allogeneic hematopoietic stem cell transplantation. In mature normal hematopoietic cells, we detected Siglec-6 in a proportion of memory (and naïve) B cells and basophilic granulocytes, suggesting the potential for limited on-target/off-tumor reactivity. The lack of expression of Siglec-6 on normal HSPCs is a key to differentiating it from other Siglec family members (eg, Siglec-3 [CD33]) and other CAR target antigens (eg, CD123) that are under investigation in AML, and it warrants the clinical investigation of Siglec-6 CAR T-cell therapy., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
4. Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing.
- Author
-
Ehrend E, Manns P, Harenkamp S, Seifried E, Geisen C, and Bonig H
- Subjects
- Humans, ADP-ribosyl Cyclase 1 chemistry, Antibodies, Monoclonal chemistry, Membrane Glycoproteins chemistry, Plasma chemistry
- Published
- 2021
- Full Text
- View/download PDF
5. Depletion of CD45RA + T cells: Advantages and disadvantages of different purification methods.
- Author
-
Bremm M, Krastel T, Cappel C, Zimmermann O, Pfeffermann LM, Katzki V, Bonig H, Schäfer R, Rettinger E, Merker M, Bremm S, Schaefer K, Klingebiel T, Soerensen J, Bader P, and Huenecke S
- Subjects
- Feasibility Studies, Flow Cytometry, Granulocyte Colony-Stimulating Factor immunology, Granulocyte Colony-Stimulating Factor metabolism, Humans, Leukocyte Common Antigens metabolism, Lymphocyte Depletion instrumentation, T-Lymphocyte Subsets metabolism, Lymphocyte Depletion methods, T-Lymphocyte Subsets immunology
- Abstract
Background: Recently, new advances were made regarding the depletion of CD45RA
+ naïve T cells from haploidentical grafts as they are suspected to be the most alloreactive., Methods: Within this project we investigated CD45RA-depletion from G-CSF mobilized PBSC by two different purification strategies according to GMP, specifically direct depletion of CD45RA+ cells (one-step approach), or CD34-positive selection followed by CD45RA-depletion (two-step approach)., Results: With log -3.9 and - 3.8 the depletion quality of CD45RA+ T cells was equally for both approaches together with a close to complete CD19+ B cell depletion. However, due to a high expression of CD45RA the majority of NK cells were lost within both CD45RA depletion strategies. Stem cell recovery after one-step CD45RA-depletion was at median 52.0% (range: 49.7-67.2%), which was comparable to previously published recovery data received from direct CD34 positive selection. Memory T cell recovery including CD4+ and CD8+ memory T cell subsets was statistically not differing between both purification approaches. The recovery of CD4+ and CD8+ T cells was as well similar, but overall a higher amount of cytotoxic than T-helper cells were lost as indicated by an increase of the CD4/CD8 ratio., Conclusions: CD45RA-depletion from G-CSF mobilized PBSC is feasible as one- and two-step approach and results in sufficient reduction of CD45RA+ T cells as well as B cells, but also to a co-depletion of NK cells. However, by gaining two independent cell products, the two-step approach enables the highest clinical flexibility in regard to individual graft composition with precise dosage of stem cells and T cells., (Copyright © 2021 Elsevier B.V. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
6. Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia.
- Author
-
Gang EJ, Kim HN, Hsieh YT, Ruan Y, Ogana HA, Lee S, Pham J, Geng H, Park E, Klemm L, Willman CL, Carroll WL, Mittelman SD, Orgel E, Oberley MJ, Parekh C, Abdel-Azim H, Bhojwani D, Wayne AS, De Arcangelis A, Georges-Labouesse E, Wayner E, Bonig H, Minasyan A, Ten Hoeve J, Graeber TG, Müschen M, Heisterkamp N, and Kim YM
- Subjects
- Animals, Antibodies, Neoplasm pharmacology, Antibodies, Neutralizing pharmacology, Apoptosis drug effects, Apoptosis genetics, Female, Humans, Male, Mice, Mice, Knockout, Drug Resistance, Neoplasm drug effects, Drug Resistance, Neoplasm genetics, Gene Deletion, Integrin alpha6 genetics, Integrin alpha6 metabolism, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma metabolism, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapy, Pyrimidines pharmacology
- Abstract
Resistance to multimodal chemotherapy continues to limit the prognosis of acute lymphoblastic leukemia (ALL). This occurs in part through a process called adhesion-mediated drug resistance, which depends on ALL cell adhesion to the stroma through adhesion molecules, including integrins. Integrin α6 has been implicated in minimal residual disease in ALL and in the migration of ALL cells to the central nervous system. However, it has not been evaluated in the context of chemotherapeutic resistance. Here, we show that the anti-human α6-blocking Ab P5G10 induces apoptosis in primary ALL cells in vitro and sensitizes primary ALL cells to chemotherapy or tyrosine kinase inhibition in vitro and in vivo. We further analyzed the underlying mechanism of α6-associated apoptosis using a conditional knockout model of α6 in murine BCR-ABL1+ B-cell ALL cells and showed that α6-deficient ALL cells underwent apoptosis. In vivo deletion of α6 in combination with tyrosine kinase inhibitor (TKI) treatment was more effective in eradicating ALL than treatment with a TKI (nilotinib) alone. Proteomic analysis revealed that α6 deletion in murine ALL was associated with changes in Src signaling, including the upregulation of phosphorylated Lyn (pTyr507) and Fyn (pTyr530). Thus, our data support α6 as a novel therapeutic target for ALL., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
7. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
- Author
-
Pfeffermann LM, Pfirrmann V, Huenecke S, Bremm M, Bonig H, Kvasnicka HM, Klingebiel T, Bader P, and Rettinger E
- Subjects
- Adolescent, Cells, Cultured, Cytokine-Induced Killer Cells immunology, Epstein-Barr Virus Infections immunology, Female, Graft vs Host Disease immunology, Graft vs Host Disease prevention & control, Graft vs Host Disease virology, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Immunity, Cellular, Immunotherapy, Adoptive methods, K562 Cells, T-Lymphocytes immunology, T-Lymphocytes transplantation, Virus Activation physiology, Cytokine-Induced Killer Cells transplantation, Epstein-Barr Virus Infections complications, Epstein-Barr Virus Infections therapy, Herpesvirus 4, Human immunology, Lymphoma therapy, Lymphoma virology
- Abstract
Background: Prolonged immunosuppression or delayed T-cell recovery may favor Epstein-Barr virus (EBV) infection or reactivation after allogeneic hematopoietic stem cell transplantation (HSCT), which can lead to post-transplant lymphoproliferative disease (PTLD) and high-grade malignant B-cell lymphoma. Cytokine-induced killer (CIK) cells with dual specific anti-tumor and virus-specific cellular immunity may be applied in this context., Methods: CIK cells with EBV-specificity were generated from peripheral blood mononuclear cells (PBMCs), expanded in the presence of interferon-γ, anti-CD3, interleukin (IL)-2 and IL-15 and were pulsed twice with EBV consensus peptide pool. CIK cells with EBV-specificity and conventional CIK cells were phenotypically and functionally analyzed. Additionally, CIK cells with EBV-specificity were applied to a patient with EBV-related PTLD rapidly progressing to highly aggressive B-cell lymphoma on a compassionate use basis after approval and agreement by the regulatory authorities., Results: Pre-clinical analysis showed that generation of CIK cells with EBV-specificity was feasible. In vitro cytotoxicity analyses showed increased lysis of EBV-positive target cells, enhanced proliferative capacity and increased secretion of cytolytic and proinflammatory cytokines in the presence of EBV peptide-displaying target cells. In addition, 1 week after infusion of CIK cells with EBV-specificity, the patient's highly aggressive B-cell lymphoma persistently disappeared. CIK cells with EBV-specificity remained detectable for up to 32 days after infusion and infusion did not result in acute toxicity., Discussion: The transfer of both anti-cancer potential and T-cell memory against EBV infection provided by EBV peptide-induced CIK cells might be considered a therapy for EBV-related PTLD., (Copyright © 2018 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
8. Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells.
- Author
-
Müller N, Landwehr K, Langeveld K, Stenzel J, Pouwels W, van der Hoorn MAWG, Seifried E, and Bonig H
- Subjects
- Adult, Automation, Laboratory, Cells, Cultured, Female, Graft vs Host Disease immunology, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods, Histocompatibility Testing, Humans, Immunomagnetic Separation instrumentation, Immunomagnetic Separation methods, Leukapheresis instrumentation, Leukapheresis methods, Lymphocyte Culture Test, Mixed, Male, T-Lymphocyte Subsets cytology, T-Lymphocyte Subsets immunology, Tissue Donors, Transplantation, Homologous, Young Adult, Graft vs Host Disease prevention & control, Immunologic Memory physiology, Immunotherapy, Adoptive adverse effects, Immunotherapy, Adoptive methods, Leukocyte Common Antigens metabolism, Lymphocyte Depletion instrumentation, Lymphocyte Depletion methods, T-Lymphocyte Subsets metabolism, T-Lymphocyte Subsets transplantation
- Abstract
Background Aims: For patients needing allogeneic stem cell transplantation but lacking a major histocompatibility complex (MHC)-matched donor, haplo-identical (family) donors may be an alternative. Stringent T-cell depletion required in these cases to avoid lethal graft-versus-host disease (GVHD) can delay immune reconstitution, thus impairing defense against virus reactivation and attenuating graft-versus-leukemia (GVL) activity. Several groups reported that GVHD is caused by cells residing within the naive (CD45RA
+ ) T-cell compartment and proposed use of CD45RA-depleted donor lymphocyte infusion (DLI) to accelerate immune reconstitution. We developed and tested the performance of a CD45RA depletion module for the automatic cell-processing device CliniMACS Prodigy and investigated quality attributes of the generated products., Methods: Unstimulated apheresis products from random volunteer donors were depleted of CD45RA+ cells on CliniMACS Prodigy, using Good Manufacturing Practice (GMP)-compliant reagents and methods throughout. Using phenotypic and functional in vitro assays, we assessed the cellular constitution of CD45RA-depleted products, including T-cell subset analyses, immunological memory function and allo-reactivity., Results: Selections were technically uneventful and proceeded automatically with minimal hands-on time beyond tubing set installation. Products were near-qualitatively CD45RA+ depleted, that is, largely devoid of CD45RA+ T cells but also of almost all B and natural killer cells. Naive and effector as well as γ/δ T cells were greatly reduced. The CD4:CD8 ratio was fivefold increased. Mixed lymphocyte reaction assays of the product against third-party leukocytes revealed reduced allo-reactivity compared to starting material. Anti-pathogen responses were retained., Discussion: The novel, closed, fully GMP-compatible process on Prodigy generates highly CD45RA-depleted cellular products predicted to be clinically meaningfully depleted of GvH reactivity., (Copyright © 2018 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
9. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
- Author
-
Miesbach W, Meijer K, Coppens M, Kampmann P, Klamroth R, Schutgens R, Tangelder M, Castaman G, Schwäble J, Bonig H, Seifried E, Cattaneo F, Meyer C, and Leebeek FWG
- Subjects
- Adult, Dependovirus, Female, Humans, Male, Factor IX biosynthesis, Factor IX genetics, Genetic Therapy, Genetic Vectors, Hemophilia B blood, Hemophilia B genetics, Hemophilia B therapy, Parvovirinae, Prednisolone administration & dosage
- Abstract
Gene therapy for hemophilia B aims to ameliorate bleeding risk and provide endogenous factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for FIX concentrate. AMT-060 combines an adeno-associated virus-5 (AAV5) vector with a liver-specific promoter driving expression of a codon-optimized wild-type human FIX gene. This multinational, open-label study included 10 adults with hemophilia B (FIX ≤2% of normal) and severe-bleeding phenotype. No participants tested positive for AAV5-neutralizing antibodies using a green-fluorescent protein-based assay, and all 10 were enrolled. A single dose of 5 × 10
12 or 2 × 1013 genome copies of AMT-060/kilogram was administered to 5 participants each. In the low-dose cohort, mean endogenous FIX activity increased to 4.4 IU/dL. Annualized FIX use was reduced by 81%, and mean annualized spontaneous bleeding rate (ASBR) decreased from 9.8% to 4.6% (53%). In the higher-dose cohort, mean FIX activity increased to 6.9 IU/dL. Annualized FIX use decreased by 73%, and mean ASBR declined from 3.0 to 0.9 (70%). There was no reduction in traumatic bleeds. FIX activity was stable in both cohorts, and 8 of 9 participants receiving FIX at study entry stopped prophylaxis. Limited, asymptomatic, and transient alanine aminotransferase elevations in the low-dose (n = 1) and higher-dose (n = 2) cohorts were treated with prednisolone. No decrease in FIX activity or capsid-specific T-cell responses were detected during transaminase elevations. A single infusion of AMT-060 had a positive safety profile and resulted in stable and clinically important increases in FIX activity, a marked reduction in spontaneous bleeds and FIX concentrate use, without detectable cellular immune responses against capsids. This trial was registered at www.clinicaltrials.gov as #NCT02396342; EudraCT #2013-005579-42., (© 2018 by The American Society of Hematology.)- Published
- 2018
- Full Text
- View/download PDF
10. Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells.
- Author
-
Karpova D, Ritchey JK, Holt MS, Abou-Ezzi G, Monlish D, Batoon L, Millard S, Spohn G, Wiercinska E, Chendamarai E, Yang W, Christ S, Gehrs L, Schuettpelz LG, Dembowsky K, Pettit AR, Rettig MP, Bonig H, and DiPersio JF
- Subjects
- Animals, Bone Marrow metabolism, Chemokine CXCL12 antagonists & inhibitors, Chemokine CXCL12 genetics, Chemokine CXCL12 metabolism, Mice, Mice, Transgenic, Receptors, CXCR4 genetics, Receptors, CXCR4 metabolism, Hematopoietic Stem Cell Mobilization methods, Hematopoietic Stem Cells metabolism, Receptors, CXCR4 antagonists & inhibitors, Stem Cell Niche drug effects
- Abstract
Interaction between the chemokine receptor CXCR4 and its chief ligand CXCL12 plays a critical role in the retention and migration of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow (BM) microenvironment. In this study, qualitative and quantitative effects of long-term pharmacologic inhibition of the CXCR4/CXCL12 axis on the HSPC compartment were investigated by using 3 structurally unrelated small molecule CXCR4 antagonists. A >10-fold increase in mobilization efficiency was achieved by administering the antagonists as a subcutaneous continuous infusion for 2 weeks compared to a single bolus injection. A concurrent increase in self-renewing proliferation leading to a twofold to fourfold expansion of the HSPC pool in the BM was observed. The expanded BM showed a distinct repopulating advantage when tested in serial competitive transplantation experiments. Furthermore, major changes within the HSPC niche associated with previously described HSPC expansion strategies were not detected in bones treated with a CXCR4 antagonist infusion. Our data suggest that prolonged but reversible pharmacologic blockade of the CXCR4/CXCL12 axis represents an approach that releases HSPC with efficiency superior to any other known mobilization strategy and may also serve as an effective method to expand the BM HSPC pool., (© 2017 by The American Society of Hematology.)
- Published
- 2017
- Full Text
- View/download PDF
11. Feasibility of CD3/CD19 depletion of a bone marrow graft.
- Author
-
Bonig H and Müller I
- Published
- 2016
- Full Text
- View/download PDF
12. Clinical-scale isolation of the total Aspergillus fumigatus-reactive T-helper cell repertoire for adoptive transfer.
- Author
-
Bacher P, Jochheim-Richter A, Mockel-Tenbrink N, Kniemeyer O, Wingenfeld E, Alex R, Ortigao A, Karpova D, Lehrnbecher T, Ullmann AJ, Hamprecht A, Cornely O, Brakhage AA, Assenmacher M, Bonig H, and Scheffold A
- Subjects
- Antigens, Fungal immunology, Aspergillosis immunology, Candida albicans immunology, Cytokines immunology, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Leukocytes, Mononuclear immunology, Lymphocyte Depletion methods, T-Lymphocytes, Helper-Inducer immunology, Tumor Necrosis Factor Receptor Superfamily, Member 9 metabolism, Aspergillosis therapy, Aspergillus fumigatus immunology, Cell Separation methods, Immunotherapy, Adoptive methods, Lymphocyte Activation immunology, T-Lymphocytes, Helper-Inducer transplantation
- Abstract
Background Aims: Evidence of the criticality of the adaptive immune response for controlling invasive aspergillosis has been provided. This observation is supported by the fact that invasive aspergillosis, a grave complication of allogeneic stem cell transplantation, occurs long after myeloid reconstitution in patients with low T-cell engraftment and/or on immunosuppressants. Adoptive T-cell transfer might be beneficial, but idiosyncrasies of Aspergillus fumigatus and the anti-Aspergillus immune response render established selection technologies ineffective., Methods: We developed a Good Manufacturing Practice (GMP)-compliant protocol for preparation of A. fumigatus-specific CD4+ cells by sequentially depleting regulatory and cytotoxic T cells, activating A. fumigatus-specific T-helper cells with GMP-grade A. fumigatus lysate, and immuno-magnetically isolating them via the transiently up-regulated activation marker, CD137., Results: In 13 full-scale runs, we demonstrate robustness and feasibility of the approach. From 2 × 10(9) peripheral blood mononuclear cells, we isolated 27 × 10(3)-318 × 10(3)Aspergillus-specific T-helper cells. Frequency among total T cells was increased, on average, by 200-fold. Specific studies indicate specificity and functionality: After non-specific in vitro expansion and re-stimulation with different antigens, we observed strong cytokine responses to A. fumigatus and some other fungi including Candida albicans, but none to unrelated antigens., Discussion: Our technology isolates naturally occurring Aspergillus-specific T-helper cells within 2 days of identifying the clinical indication. Rapid adoptive transfer of Aspergillus-specific T cells may be quite feasible; the clinical benefit remains to be demonstrated. A manufacturing license as an advanced-therapy medicinal product was received and a clinical trial in post-transplantation invasive aspergillosis patients approved. The product is dosed at 5 × 10E3/kg T cells (single intravenous injection), of which at least 10% must be A. fumigatus-specific., (Copyright © 2015 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
13. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
- Author
-
Pfirrmann V, Oelsner S, Rettinger E, Huenecke S, Bonig H, Merker M, Wels WS, Cinatl J, Schubert R, Klingebiel T, and Bader P
- Subjects
- Cell Line, Tumor, Cytokine-Induced Killer Cells cytology, Cytomegalovirus immunology, Cytomegalovirus Infections virology, Cytotoxicity, Immunologic drug effects, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Interferon-gamma pharmacology, Interleukin-15 pharmacology, Interleukin-2 pharmacology, Leukemia pathology, Leukemia therapy, Phosphoproteins immunology, Stem Cell Transplantation, T-Lymphocytes, Cytotoxic immunology, Viral Matrix Proteins immunology, Cell- and Tissue-Based Therapy methods, Cytokine-Induced Killer Cells transplantation, Cytomegalovirus Infections therapy, Immunotherapy methods
- Abstract
Background Aims: Human cytomegalovirus (CMV) infection and reactivation is a leading complication of allogeneic hematopoietic stem cell transplantation (HSCT). In addition to drug treatment, the adoptive transfer of virus-specific T cells to restore cellular immunity has become a standard therapy after allogeneic HSCT. We recently demonstrated potent anti-leukemic activity of interleukin (IL)-15-activated cytokine-induced killer (CIK) cells. With the use of the same expansion protocol, we asked whether concurrent CMV antigen-pulsing might generate CIK cells with anti-leukemic and anti-CMV activity., Methods: CIK cells expanded in the presence of interferon-γ, IL-2, IL-15 and anti-CD3 antibody were pulsed once with CMV(pp65) peptide pool. CMV-specific CIK (CIK(pp65)) and conventional CIK cells were phenotypically and functionally characterized according to their cytokine secretion pattern, degranulation capacity and T-cell receptor (TCR)-mediated and NKG2D-mediated cytotoxicity., Results: We demonstrated that among CIK cells generated from CMV-seropositive donors, a single stimulation with CMV(pp65) protein co-expanded cytotoxic CMV-specific cells without sacrificing anti-tumor reactivity. Cells generated in this fashion lysed CMV(pp65)-loaded target cells and CMV-infected fibroblasts but also leukemic cells. Meanwhile, the alloreactive potential of CIK(pp65) cells remained low. Interestingly, CMV reactivity was TCR-mediated and CMV-specific cells could be found in CD3(+)CD8(+)CD56(+/-) cytotoxic T-cell subpopulations., Conclusions: We provide an efficient method to generate CIK(pp65) cells that may represent a useful cell therapy approach for preemptive immunotherapy in patients who have both an apparent risk of CMV and impending leukemic relapse after allogeneic stem cell transplantation., (Copyright © 2015 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
14. RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation.
- Author
-
Kuvardina ON, Herglotz J, Kolodziej S, Kohrs N, Herkt S, Wojcik B, Oellerich T, Corso J, Behrens K, Kumar A, Hussong H, Urlaub H, Koch J, Serve H, Bonig H, Stocking C, Rieger MA, and Lausen J
- Subjects
- Antigens, CD34 genetics, Antigens, CD34 metabolism, Basic Helix-Loop-Helix Transcription Factors genetics, Basic Helix-Loop-Helix Transcription Factors metabolism, Core Binding Factor Alpha 2 Subunit genetics, Erythroid Precursor Cells cytology, Erythroid Precursor Cells metabolism, Erythropoiesis physiology, Humans, K562 Cells, Kruppel-Like Transcription Factors genetics, Kruppel-Like Transcription Factors metabolism, Megakaryocyte Progenitor Cells cytology, Megakaryocyte Progenitor Cells metabolism, Megakaryocytes cytology, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism, T-Cell Acute Lymphocytic Leukemia Protein 1, Cell Differentiation physiology, Core Binding Factor Alpha 2 Subunit metabolism, Gene Expression Regulation physiology, Megakaryocytes metabolism, Thrombopoiesis physiology
- Abstract
The activity of antagonizing transcription factors represents a mechanistic paradigm of bidirectional lineage-fate control during hematopoiesis. At the megakaryocytic/erythroid bifurcation, the cross-antagonism of krueppel-like factor 1 (KLF1) and friend leukemia integration 1 (FLI1) has such a decisive role. However, how this antagonism is resolved during lineage specification is poorly understood. We found that runt-related transcription factor 1 (RUNX1) inhibits erythroid differentiation of murine megakaryocytic/erythroid progenitors and primary human CD34(+) progenitor cells. We show that RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation by epigenetic repression of the erythroid master regulator KLF1. RUNX1 binding to the KLF1 locus is increased during megakaryocytic differentiation and counterbalances the activating role of T-cell acute lymphocytic leukemia 1 (TAL1). We found that corepressor recruitment by RUNX1 contributes to a block of the KLF1-dependent erythroid gene expression program. Our data indicate that the repressive function of RUNX1 influences the balance between erythroid and megakaryocytic differentiation by shifting the balance between KLF1 and FLI1 in the direction of FLI1. Taken together, we show that RUNX1 is a key player within a network of transcription factors that represses the erythroid gene expression program., (© 2015 by The American Society of Hematology.)
- Published
- 2015
- Full Text
- View/download PDF
15. Multi-site evaluation of the BD Stem Cell Enumeration Kit for CD34(+) cell enumeration on the BD FACSCanto II and BD FACSCalibur flow cytometers.
- Author
-
Preti RA, Chan WS, Kurtzberg J, Dornsife RE, Wallace PK, Furlage R, Lin A, Omana-Zapata I, Bonig H, and Tonn T
- Subjects
- Antigens, CD34 immunology, Cell Count, Cell Lineage genetics, Fetal Blood cytology, Fetal Blood immunology, Flow Cytometry instrumentation, Humans, Stem Cells immunology, Antigens, CD34 metabolism, Flow Cytometry methods, Stem Cell Transplantation, Stem Cells cytology
- Abstract
Background Aims: Evaluation of the BD Stem Cell Enumeration Kit was conducted at four clinical sites with flow cytometry CD34(+) enumeration to assess agreement between two investigational methods: (i) the BD FACSCanto II and BD FACSCalibur systems and (ii) the predicate method (Beckman Coulter StemKit and StemTrol, Immunotech SAS, Beckman Coulter, Marseille Cedex 9, France)., Methods: Leftover and delinked specimens (n = 1032) from clinical flow cytometry testing were analyzed on the BD FACSCanto II (n = 918) and BD FACSCalibur (n = 905) in normal and mobilized blood, frozen and thawed bone marrow and leucopheresis and cord blood anticoagulated with citrate phosphate dextrose, anticoagulant citrate dextrose-solution A, heparin and ethylenediaminetetraacetate, alone or in combination. Fresh leucopheresis analysis addressed site equivalency for sample preparation, testing and analysis., Results: The mean relative bias showed agreement within predefined parameters for the BD FACSCanto II (-2.81 to 4.31 ±7.1) and BD FACSCalibur (-2.69 to 5.2 ±7.9). Results are reported as absolute and relative differences compared with the predicate for viable CD34(+), percentage of CD34(+) in CD45(+) and viable CD45(+) populations (or gates). Bias analyses of the distribution of the predicate low, mid and high bin values were done using BD FACSCanto II optimal gating and BD FACSCalibur manual gating for viable CD34(+), percentage of CD34(+) in CD45(+) and viable CD45(+). Bias results from both investigational methods show agreement. Deming regression analyses showed a linear relationship with R(2) > 0.92 for both investigational methods., Discussion: In conclusion, the results from both investigational methods demonstrated agreement and equivalence with the predicate method for enumeration of absolute viable CD34(+), percentage of viable CD34(+) in CD45(+) and absolute viable CD45(+) populations., (Copyright © 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
16. Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion.
- Author
-
Rettinger E, Kreyenberg H, Merker M, Kuçi S, Willasch A, Bug G, Ullrich E, Wels WS, Bonig H, Klingebiel T, and Bader P
- Subjects
- Animals, Cytokine-Induced Killer Cells cytology, Cytotoxicity, Immunologic immunology, Disease-Free Survival, Hematopoietic Stem Cell Transplantation methods, Humans, Lymphocytes cytology, Lymphocytes immunology, Mice, Neoplasm Recurrence, Local therapy, Stem Cell Transplantation methods, Cytokine-Induced Killer Cells immunology, Immunomagnetic Separation, Neoplasm Recurrence, Local immunology, Transplantation, Homologous methods
- Abstract
Background Aims: Cytokine-induced killer (CIK) cells may offer a novel therapeutic approach for patients with malignancies relapsing after allogeneic stem cell transplantation. Although CIK cells display negligible alloreactivity and cause minimal graft versus-host-disease (GVHD), high CIK cell doses required during relapse may pose a risk for severe GVHD, specifically in the mismatched or haploidentical transplantation setting. Manipulation of CIK cells may reduce risk for GVHD without affecting the anti-tumor potential., Methods: In this pre-clinical study, we provide a detailed functional comparison of conventional and irradiated, CD56-enriched or T-cell receptor α/β-depleted CIK cells., Results: In vitro analysis showed retained anti-leukemic and anti-tumor potential after CIK cell manipulation. Even being sequentially infused into immunodeficient mice grafted with malignant cells, cytotoxic effects were fewest after irradiation but were improved by CD56 enrichment and were best with conventional CIK cells. Hence, considering the proliferative capacity of inoculated malignancies and effector cells, a single dose of conventional CIK cells resulted in prolonged disease-free survival and elimination of rhabdomyosarcoma cells, whereas sequential infusions were needed to achieve comparable results in leukemia-bearing mice. However, this mouse model has limitations: highly effective conventional CIK cells demonstrated both limited xenogenic GVHD and low alloreactive potential in vitro., Conclusions: Our study revealed that conventional CIK cells demonstrate no significant alloreactive potential but provide the strongest anti-tumor efficacy compared with manipulated CIK cells. Conventional CIK cells may therefore be tested in high numbers and short-term intervals in patients with impending relapse even after mismatched transplantation., (Copyright © 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
17. Enumeration of viable CD34(+) cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD™ stem cell enumeration kit.
- Author
-
Dauber K, Becker D, Odendahl M, Seifried E, Bonig H, and Tonn T
- Subjects
- Antigens, CD34, Humans, Bone Marrow Cells cytology, Bone Marrow Cells metabolism, Cell Count methods, Fetal Blood cytology, Fetal Blood metabolism, Flow Cytometry methods, Stem Cells cytology, Stem Cells metabolism
- Abstract
Background Aims: Enumeration of CD34(+) cells in leukocyte-rich cell suspensions is important for clinical decision-making in stem cell transplantation. Single-platform flow cytometry assays offer the significant advantages of speed and reproducibility, and have therefore become the gold standard in stem cell enumeration. The clinical community has recently defined the need for stem cell enumeration kits that incorporate viability dyes. The purpose of this study was to evaluate a novel assay, BD Biosciences' (BD) stem cell enumeration kit (SCE kit(‡)), in relation to Beckman Coulter's (BC) commercially available BC Stem-Kit™., Methods: Fresh/freeze-thawed samples from leukapheresis, bone marrow and cord blood, and fresh normal/mobilized blood, were analyzed with both assays (simultaneous detection of side/forward scatter and three fluorescence signals) on two flow cytometry platforms, BD FACSCanto II and BD FACSCalibur. Results. Results from both assays were highly congruent, with an overall r(2) ≥ 0.99 (all specimen types included), a linear correlation across all CD34(+) cell frequencies and concentrations, and an almost ideal steepness of the trend line., Conclusions: Both assays functioned reliably. Being based on single-platform International Society of Hematotherapy and Graft Engineering (ISHAGE) guidelines and similar staining methods, both assays essentially come to identical results. For most specimen types, the viability of CD34(+) cells was equal to overall leukocyte viability. In summary, in the hands of an experienced technician, the BD™ SCE kit and the BC Stem-Kit are equivalent. The infrequent user might derive benefit from the fact that counting spheres are pre-pipetted into the Trucount tube for the SCE kit, making this assay less susceptible to pipetting inaccuracy.
- Published
- 2011
- Full Text
- View/download PDF
18. On the adaptation of endosteal stem cell niche function in response to stress.
- Author
-
Jiang Y, Bonig H, Ulyanova T, Chang K, and Papayannopoulou T
- Subjects
- Animals, Chemokine CXCL12 genetics, Chemokine CXCL12 metabolism, GTP-Binding Protein alpha Subunits, Gi-Go genetics, GTP-Binding Protein alpha Subunits, Gi-Go metabolism, Integrin alpha4 genetics, Integrin alpha4 metabolism, Mice, Mice, Knockout, Pertussis Toxin genetics, Pertussis Toxin metabolism, Proto-Oncogene Proteins c-kit, Signal Transduction drug effects, Signal Transduction genetics, Whole-Body Irradiation, Bone Marrow metabolism, Stem Cell Transplantation, Stem Cells metabolism, Stress, Physiological
- Abstract
Although the influence of microenvironmental "niche" on the function of a variety of stem cells is undisputed, the details of hematopoietic stem cell/niche interactions at the cellular and molecular level have sparked a continuous debate. We studied the microanatomic partitioning of transplanted normal and alpha4 integrin-deficient Lin-kit+ cells in trabecular and compact bone before and after irradiation and present robust quantitative data on both. We found that (1) the microanatomic distribution of normal highly enriched progenitor cells is random in nonirradiated recipients based on area distribution analyses, (2) in contrast, in irradiated hosts normal cells distribute preferentially near the endosteum, (3) the overall cell seeding efficiency was higher in trabecular versus compact bone both before and after irradiation, and (4) alpha4 integrin-deficient cells not only lodge with reduced overall efficiency confirming previous data, but fail to preferentially partition themselves into endosteal regions in irradiated hosts, as normal cells do. A similar phenotype was observed with cells rendered G(i)-protein signaling incompetent by pertussis toxin treatment, supporting an active stromal-derived factor 1 (SDF-1) gradient near endosteum after irradiation.
- Published
- 2009
- Full Text
- View/download PDF
19. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.
- Author
-
Bonig H, Wundes A, Chang KH, Lucas S, and Papayannopoulou T
- Subjects
- Animals, Antibodies, Monoclonal immunology, Antibodies, Monoclonal, Humanized, Antigens, CD34 immunology, Colony-Forming Units Assay, Dose-Response Relationship, Drug, Female, Haplorhini, Hematopoietic Stem Cell Mobilization, Humans, Inflammation blood, Inflammation drug therapy, Inflammation immunology, Integrin alpha4 immunology, Lymphocytes immunology, Male, Mice, Mice, SCID, Multiple Sclerosis blood, Multiple Sclerosis immunology, Natalizumab, Time Factors, Antibodies, Monoclonal administration & dosage, Hematopoietic Stem Cells immunology, Multiple Sclerosis drug therapy
- Abstract
Blockade of CD49d-mediated lymphocyte trafficking has been used therapeutically for certain autoimmune diseases, such as multiple sclerosis (MS). In addition to negative effects on the trafficking of mature lymphocytes to sites of inflammation, CD49d blockade in mice and monkeys rapidly mobilizes hematopoietic stem/progenitor cells (HSPCs) capable of short- and long-term engraftment. Here we aimed to ascertain the effects of treatment with antifunctional anti-CD49d antibody in humans (MS patients receiving infusions of the CD49d-blocking antibody natalizumab) on levels of circulating HSPCs after a single dose of antibody or after long-term treatment. On average, 6-fold elevated levels of circulating CD34+ cells and colony-forming unit-culture (CFU-C) were achieved within 1 day of the first dose of natalizumab, and similar levels were continuously maintained under monthly natalizumab infusions. The blood of natalizumab-treated subjects also contained SCID-repopulating cells. The fate of these circulating HSPCs and their clinical relevance for MS patients remains to be determined.
- Published
- 2008
- Full Text
- View/download PDF
20. The p67 laminin receptor identifies human erythroid progenitor and precursor cells and is functionally important for their bone marrow lodgment.
- Author
-
Bonig H, Chang KH, Nakamoto B, and Papayannopoulou T
- Subjects
- Adult, Animals, Antibodies pharmacology, Bone Marrow metabolism, Cells, Cultured, Erythroid Precursor Cells transplantation, Flow Cytometry, Gene Expression Regulation, Granulocyte Precursor Cells metabolism, Humans, Mice, Mice, Knockout, Neoplasms metabolism, Receptors, Laminin antagonists & inhibitors, Stromal Cells metabolism, Antigens, CD34 biosynthesis, Erythroid Precursor Cells metabolism, Receptors, Laminin biosynthesis
- Abstract
The laminins are a group of extracellular matrix proteins with constitutive expression in all tissues, including bone marrow stroma. A functional role for the nonintegrin laminin receptor p67 has been described for cancer metastasis and lymphocyte trafficking. Expression of p67 was also reported for other subsets of mature leukocytes and for malignant hematopoietic or nonhematopoietic cells. We explored p67 expression on normal hematopoietic progenitor cells (HPCs) and its putative role in bone marrow retention of transplanted HPCs. We found p67 expression on a subset of primary human CD34(+) cells coexpressing erythroid markers. Of importance, p67 recognizes early erythroid progenitors, since sorted p67(+) cells were significantly enriched for burst-forming units-erythroid (BFU-Es) and depleted of colony-forming units--granulocyte/macrophage (CFU-GMs). Blockade of p67 binding of donor cells, using antifunctional antibody, reduced bone marrow homing of BFU-Es. These studies identify p67 as a novel phenotypic marker for erythroid HPCs of functional importance for lineage-specific homing/retention among adult transplanted HPCs.
- Published
- 2006
- Full Text
- View/download PDF
21. Hierarchy of molecular-pathway usage in bone marrow homing and its shift by cytokines.
- Author
-
Bonig H, Priestley GV, and Papayannopoulou T
- Subjects
- Animals, Chemokine CXCL12, Chemokines, CXC metabolism, Chemokines, CXC physiology, Cytokines metabolism, GTP-Binding Protein alpha Subunits, Gi-Go metabolism, Integrin alpha4 genetics, Integrin alpha4 metabolism, Integrin alpha4 physiology, Mice, Mice, Knockout, Receptors, CXCR4 metabolism, Receptors, CXCR4 physiology, Signal Transduction, Vascular Cell Adhesion Molecule-1 genetics, Vascular Cell Adhesion Molecule-1 metabolism, Vascular Cell Adhesion Molecule-1 physiology, Bone Marrow physiology, Cell Movement physiology, Cytokines physiology, Hematopoietic Stem Cells cytology
- Abstract
Efficient bone marrow (BM) homing is a prerequisite for successful engraftment of transplanted hematopoietic cells (HPCs). Contradictory conclusions about the contribution of SDF-1/CXCR4 have clouded our understanding of its role within the molecular pathway cooperation needed for BM homing, particularly with the well-defined hierarchic network of adhesion molecules. In the present study we sought to unravel cooperative and compensatory molecular pathways guiding BM homing. Fresh BM-HPCs, rendered either SDF-1 unresponsive or Gi-signaling refractory, homed quite efficiently, because of compensation by alpha4-integrin interacting with VCAM-1. The contribution of SDF-1/CXCR4- or Gi-protein-mediated signals to BM homing became apparent after their blockade was combined with deletion of alpha4-integrin, leading to dramatic reduction in BM homing. Similar conclusions were revealed when VCAM-1-deficient hosts were used. Cytokine incubation changed the functional properties of BM-HPCs and hierarchy of molecular pathway usage in homing, by shifting the dominance among the homing mediators: loss of CXCR4 or Gi-signaling now significantly reduced BM homing, with only partial compensation through alpha4/VCAM-1 and endothelial selectins. These studies depict a flexible hierarchy of cooperating homing pathways, in which dominant players are repositioned with changing cytokine milieu, and possibly source of HPCs.
- Published
- 2006
- Full Text
- View/download PDF
22. PTX-sensitive signals in bone marrow homing of fetal and adult hematopoietic progenitor cells.
- Author
-
Bonig H, Priestley GV, Nilsson LM, Jiang Y, and Papayannopoulou T
- Subjects
- Actins metabolism, Aging physiology, Animals, Bone Marrow Cells cytology, Bone Marrow Cells metabolism, Cell Differentiation drug effects, Fetus cytology, GTP-Binding Proteins metabolism, Humans, Jurkat Cells, Kinetics, Liver cytology, Liver drug effects, Liver metabolism, Proto-Oncogene Proteins c-kit metabolism, Ribose metabolism, Bone Marrow Cells drug effects, Cell Movement drug effects, Fetus drug effects, Hematopoietic Stem Cells cytology, Hematopoietic Stem Cells drug effects, Pertussis Toxin pharmacology, Signal Transduction drug effects
- Abstract
Several examples suggest a relationship between in vitro migratory capacity and bone marrow (BM) homing. Pertussis toxin (PTX) is a potent inhibitor of serpentine receptor-associated inhibitory trimeric guanidine nucleotide binding (Gi) protein signals. As such, it blocks hematopoietic progenitor cell migration in vitro, but contrary to expectation, no effects on BM homing were observed in previous studies. We therefore re-examined the effect of PTX on homing of murine BM and fetal liver (FL). We found that BM homing of PTX-incubated progenitor cells (colony-forming cells in culture [CFU-Cs]) from BM or FL in irradiated and nonirradiated recipients was reduced by more than 75%, with a concomitant increase in circulating CFU-Cs in peripheral blood. Additional studies confirmed the functional significance of this reduction in homing: PTX-treated cells did not provide radioprotection, and their short-term engraftment in BM and spleen was drastically reduced. Furthermore, several approaches show that cell-intrinsic rather than host-derived mechanisms are responsible for the PTX-induced homing defect. In summary, we show that Gi protein signals are required for BM homing and, as such, provide a new example of the association between BM homing and in vitro migration. Moreover, our data suggest that the behavior of hematopoietic progenitors in obeying Gi signaling does not diverge from that of mature leukocytes.
- Published
- 2004
- Full Text
- View/download PDF
23. The role of G-protein signaling in hematopoietic stem/progenitor cell mobilization.
- Author
-
Papayannopoulou T, Priestley GV, Bonig H, and Nakamoto B
- Subjects
- Animals, Antibodies pharmacology, Bone Marrow Cells cytology, Bone Marrow Cells immunology, CD18 Antigens physiology, Cell Movement, Chemokine CCL2 deficiency, Colony-Forming Units Assay, Drug Synergism, Granulocyte Colony-Stimulating Factor pharmacology, Hematopoietic Stem Cells immunology, Immunophenotyping, Integrin alpha4 immunology, Integrin alpha4beta1 antagonists & inhibitors, Kinetics, Leukocytosis, Matrix Metalloproteinase 9 deficiency, Matrix Metalloproteinase 9 physiology, Mice, Mice, Knockout, Mice, Transgenic, Pertussis Toxin pharmacology, Polysaccharides pharmacology, Receptors, Granulocyte Colony-Stimulating Factor deficiency, Selectins physiology, Spleen cytology, Stem Cells immunology, GTP-Binding Proteins physiology, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cells cytology, Signal Transduction, Stem Cells cytology
- Abstract
The directed migration of mature leukocytes to inflammatory sites and the lymphocyte trafficking in vivo are dependent on G protein-coupled receptors and delivered through pertussis toxin (Ptx)-sensitive Gi-protein signaling. In the present study, we explored the in vivo role of G-protein signaling on the redistribution or mobilization of hematopoietic stem/progenitor cells (HPCs). A single injection of Ptx in mice elicits a long-lasting leukocytosis and a progressive increase in circulating colony-forming unit-culture (CFU-C) and colony-forming unit spleen (CFU-S). We found that the prolonged effect is sustained by a continuous slow release of Ptx bound to red blood cells or other cells and is potentially enhanced by an indirect influence on cell proliferation. Plasma levels of certain cytokines (interleukin 6 [IL-6], granulocyte colony-stimulating factor [G-CSF]) increase days after Ptx treatment, but these are unlikely initiators of mobilization. In addition to normal mice, mice genetically deficient in monocyte chemotactic protein 1 (MCP-1), matrix metalloproteinase 9 (MMP-9), G-CSF receptor, beta2 integrins, or selectins responded to Ptx treatment, suggesting independence of Ptx-response from the expression of these molecules. Combined treatments of Ptx with anti-very late activation antigen (anti-VLA-4), uncovered potentially important insight in the interplay of chemokines/integrins, and the synergy of Ptx with G-CSF appeared to be dependent on MMP-9. As Ptx-mobilized kit+ cells display virtually no response to stromal-derived factor 1 (SDF-1) in vitro, our data suggest that disruption of CXCR4/SDF-1 signaling may be the underlying mechanism of Ptx-induced mobilization and indirectly reinforce the notion that active signaling through this pathway is required for continuous retention of cells within the bone marrow. Collectively, our data unveil a novel example of mobilization through pharmacologic modulation of signaling.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.